AMGN
NASDAQAmgen Inc.
Price$404.34-3.84 (-0.94%)
01:30 PM02:00 PM
News · 26 weeks108-29%
2026-04-122026-10-04
Mix3490d
- Analyst10(29%)
- Insider8(24%)
- Dividends7(21%)
- Other6(18%)
- SEC Filings2(6%)
- Earnings1(3%)
Latest news
25 items- FDAFDA Approval for RIABNI issued to AMGEN INCSubmission status for AMGEN INC's drug RIABNI (SUPPL-5) with active ingredient RITUXIMAB-ARRX has changed to 'Approval' on 09/29/2026. Application Category: BLA, Application Number: 761140, Application Classification:
- PRKRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034SAN DIEGO, Sept. 28, 2026 /CNW/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected to account for nearly 70% of the total. As the first generation of RAS-targeted drugs gives way to broader multi-selective inhibitors, the field's central question
- PRAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASEDazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.The study met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement at Week 48, as measured by the EULAR Sjögren's Syndrome Disease Activity Index
- FDAFDA Approval for IMDELLTRA issued to AMGEN INCSubmission status for AMGEN INC's drug IMDELLTRA (SUPPL-2) with active ingredient TARLATAMAB-DLLE has changed to 'Approval' on 09/11/2026. Application Category: BLA, Application Number: 761344, Application Classification:
- PRFDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-Stage Small Cell Lung CancerTHOUSAND OAKS, Calif., Sept. 14, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved an update to the IMDELLTRA® (tarlatamab-dlle) Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in an appropriate healthcare setting.This approval means that patients receiving IMDELLTRA should now be monitored for 6 to 8 hours from the start of their first two infusions, compared with the previously recommended 22 to 24 hours. Patients will also receiv
- PRAMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCETHOUSAND OAKS, Calif., Sept. 9, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m. ET on Tuesday, September 15, 2026. Jay Bradner, executive vice president, Research and Development, Artificial Intelligence and Data at Amgen, and Thomas Dittrich, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain invest
- PRIMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERPhase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab AloneStudy Also Met Secondary Progression-Free Survival and Objective Response Rate Endpoints THOUSAND OAKS, Calif., Sept. 8, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced landmark results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone. This study tested IMDELLTRA as a first-line maintena
- ANALYSTAmgen downgraded by BMO Capital Markets with a new price targetBMO Capital Markets downgraded Amgen from Outperform to Market Perform and set a new price target of $450.00
- INSIDERNew insider Dittrich Thomas J.W. claimed ownership of 16,860 shares (SEC Form 3)3 - AMGEN INC (0000318154) (Issuer)
- PRAMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCETHOUSAND OAKS, Calif., Sept. 2, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026. Thomas Dittrich, executive vice president and chief financial officer at Amgen, Paul Burton, M.D., Ph.D, senior vice president and chief medical officer at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in Amgen's business
- PRAMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKERepatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 TrialSeparate Global Real-World Analyses Show Persistent Gaps in Lipid Management, With Many High-Risk Patients Undertreated and Not Achieving Recommended LDL-C GoalsTHOUSAND OAKS, Calif., Aug. 31, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments. The results are from a pre-specified a
- PRTEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTSStatistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE THOUSAND OAKS, Calif., Aug. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE® (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE). TEZSPIRE demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52. The co-primary endpoints were histologic
- INSIDERSVP, Business Development Khosla Rachna exercised 1,252 shares at a strike of $162.60 and sold $1,346,499 worth of shares (3,252 units at $414.05), decreasing direct ownership by 24% to 6,404 units (SEC Form 4) to satisfy tax liability4 - AMGEN INC (0000318154) (Issuer)
- INSIDERVP, Finance & CAO Busch Matthew C. was granted 730 shares, increasing direct ownership by 17% to 5,080 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Ishrak Omar was granted 85 shares, increasing direct ownership by 1% to 7,486 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Holley Charles M was granted 103 shares, increasing direct ownership by 0.80% to 12,990 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Drake Michael V was granted 64 shares, increasing direct ownership by 1% to 5,876 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERSVP, Human Resources Miller Derek exercised 3,890 shares at a strike of $169.56 and sold $1,565,898 worth of shares (3,890 units at $402.54) (SEC Form 4) (tax liability)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERSVP & CCO Grygiel Nancy A. exercised 2,970 shares at a strike of $177.41 and sold $1,194,415 worth of shares (2,970 units at $402.16) (SEC Form 4) (for withholding tax)4 - AMGEN INC (0000318154) (Issuer)
- ANALYSTTruist reiterated coverage on Amgen with a new price targetTruist reiterated coverage of Amgen with a rating of Hold and set a new price target of $362.00 from $340.00 previously
- ANALYSTOppenheimer reiterated coverage on Amgen with a new price targetOppenheimer reiterated coverage of Amgen with a rating of Outperform and set a new price target of $450.00 from $400.00 previously
- ANALYSTMorgan Stanley reiterated coverage on Amgen with a new price targetMorgan Stanley reiterated coverage of Amgen with a rating of Equal-Weight and set a new price target of $351.00 from $333.00 previously
- ANALYSTRBC Capital Mkts reiterated coverage on Amgen with a new price targetRBC Capital Mkts reiterated coverage of Amgen with a rating of Outperform and set a new price target of $400.00 from $370.00 previously
- ANALYSTRobert W. Baird reiterated coverage on Amgen with a new price targetRobert W. Baird reiterated coverage of Amgen with a rating of Underperform and set a new price target of $230.00 from $215.00 previously
- ANALYSTBofA Securities reiterated coverage on Amgen with a new price targetBofA Securities reiterated coverage of Amgen with a rating of Underperform and set a new price target of $317.00 from $312.00 previously
AMGN FAQ
8 questionsWhat does Amgen Inc. do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic...Where does AMGN stock trade?
Amgen Inc. (AMGN) is listed on NASDAQ.What sector and industry is AMGN in?
Amgen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Amgen Inc. go public?
Amgen Inc. (AMGN) completed its IPO in 1983.Does AMGN pay a dividend?
AMGN's most recent ex-dividend date was 2026-08-21 with a cash dividend of $2.52 per share. No future ex-date is on file yet.What are analysts saying about AMGN?
Amgen Inc. has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Market Perform on 2026-09-08.What companies are similar to AMGN?
Notable peers in the same industry include ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG), AZN (AstraZeneca PLC), PFE (Pfizer Inc.). Compare AMGN side-by-side with any of them on Quantisnow.How can I track AMGN on Quantisnow?
Quantisnow aggregates Amgen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMGN to receive live email and push alerts on every new disclosure.